Effect of Ertugliflozin on Cardiac Function in Diabetes
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The aim of this study is to investigate the beneficial role of ertugliflozin, a new SGLT2
inhibitor, in cardiac function via measuring GLS as well as other hemodynamic factors using
echocardiogram in patients with T2D and HF, who are not controlled with oral antidiabetic
medications including DPP4 inhibitors.
Phase:
Phase 3
Details
Lead Sponsor:
Soo Lim
Collaborator:
MSD Korea Ltd.
Treatments:
Dipeptidyl-Peptidase IV Inhibitors Ertugliflozin Metformin